Trials / Completed
CompletedNCT05855967
A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India
A 24-Week Multicenter, Open-label, Single-arm, Phase 4 Study to Evaluate the Safety of Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis or Active Psoriatic Arthritis in India
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 250 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to investigate the safety and tolerability of ixekizumab in participants in India with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixekizumab | Administered SC |
Timeline
- Start date
- 2023-06-27
- Primary completion
- 2024-08-08
- Completion
- 2024-09-23
- First posted
- 2023-05-12
- Last updated
- 2025-08-22
- Results posted
- 2025-08-22
Locations
14 sites across 1 country: India
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05855967. Inclusion in this directory is not an endorsement.